IL-11 gene silencing

IL-11 gene silencing uses RNA interference to reduce production of the il-11 ligand upstream of il-11-signaling. The represented intervention is a lipid-nanoparticle siRNA formulation tested in middle-aged mice and rats; it is not an antibody and is not an approved siRNA product.

Ovarian-aging evidence

Wu et al. administered control or siIl11 lipid nanoparticles by tail vein twice weekly for four weeks to 36-week-old mice and 40-week-old rats ¹. In mice, the treatment reduced ovarian stiffness by 35.7% relative to control siRNA, lowered collagen/ACTA2/pERK measures and improved selected follicle and ovulation endpoints. Rat results converged for stiffness, fibrosis, follicle counts and litter size.

Pregnancy proportions moved in a favorable direction but were not statistically established when recalculated from the source counts: mouse 3/8 versus 6/8 (two-sided Fisher P≈0.315) and rat 3/10 versus 6/10 (P≈0.370). The paper printed P=0.0004 and P=3.34×10−5 for those contrasts, which are irreconcilable with the stated counts. Mouse litter size was higher among pregnancies, but the caption and source workbook disagree on treated n (5 versus 6). These discrepancies preclude a pregnancy-efficacy claim.

The evidence is preclinical and preventive/attenuating: treatment began during a rapid middle-age decline window, not after advanced fibrosis was demonstrated. The injection volume was reported, but the siRNA concentration or mass dose was not. Tail-vein nanoparticles were not ovary-specific, so extra-ovarian effects could contribute.

Distinction from AAV and antibodies

The same study used local ovarian-bursal AAV-shIl11ra1 as a separate gene-therapy-style experiment targeting the receptor. Vector serotype, construct/promoter, shRNA sequence, genome dose/titer, injection volume, vendor, control-vector identity and biodistribution were not reported. It should not be treated as the same pharmacological product as siIl11 nanoparticles.

Likewise, anti-il-11-antibodies are a distinct modality. No antibody was used as an in-vivo ovarian intervention in Wu et al.; antibody evidence was confined to cultured human ovarian fibroblasts.

Translation gaps

• Dose, control-siRNA sequence, pharmacokinetics, biodistribution and duration of ovarian knockdown were insufficiently characterized.
• There was no dedicated systemic toxicology, immune, wound-healing or reproductive-safety package.
• Long-term endocrine function, menopause timing and offspring health were not established.
• Partial adult suppression must be distinguished from germline Il11/Il11ra1 loss, which produced ligand-null female infertility and ligand-null male subfertility, plus receptor-null-specific craniofacial and bone phenotypes, in the compared mouse lines ².

Date-filtered PubMed and Europe PMC searches found other preclinical IL-11 siRNA delivery systems for lung fibrosis and wound healing, but no human trial and no later ovarian-aging study that resolves Wu et al.’s missing dose, biodistribution, pregnancy-statistics or offspring-safety questions.

gap/needs-replication gap/needs-human-replication gap/dose-response-unclear gap/long-term-unknown

Footnotes

Footnotes

1. wu-2026-il11-ovarian-stiffness · doi:10.1038/s43587-026-01159-2 · Wu M et al. · Nature Aging 2026;6:1395–1416 · systemic siIl11 nanoparticle experiments in mice and rats plus local ovarian AAV-shIl11ra1 in mice ↩

2. ng-2021-il11-il11ra1-loss-of-function · doi:10.1038/s41598-021-93623-9 · Ng B et al. · Scientific Reports 2021;11:14088 · constitutive mouse ligand/receptor loss-of-function phenotyping ↩